Disposition of 8013 shares by Kapadia Sandip of Harmony Biosciences at 33.58 subject to Rule 16b-3
| HRMY Stock | USD 33.47 3.50 9.47% |
Slightly above 60% of Harmony Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Harmony Biosciences Holdings stock suggests that many investors are alarmed at this time. Harmony Biosciences' investing sentiment can be driven by a variety of factors including economic data, Harmony Biosciences' earnings reports, geopolitical events, and overall market trends.
Harmony |
Filed transaction by Harmony Biosciences Holdings Officer Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Harmony Biosciences Fundamental Analysis
We analyze Harmony Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harmony Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harmony Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Harmony Biosciences is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Harmony Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Harmony Biosciences stock to make a market-neutral strategy. Peer analysis of Harmony Biosciences could also be used in its relative valuation, which is a method of valuing Harmony Biosciences by comparing valuation metrics with similar companies.
Peers
Harmony Biosciences Related Equities
| PTGX | Protagonist Therapeutics | 3.02 | ||||
| SNDX | Syndax Pharmaceuticals | 2.17 | ||||
| TVTX | Travere Therapeutics | 1.84 | ||||
| VRNA | Verona Pharma | 1.81 | ||||
| INZY | Inozyme Pharma | 1.68 | ||||
| NUVL | Nuvalent | 1.52 | ||||
| VTYX | Ventyx Biosciences | 0.66 | ||||
| FENC | Fennec Pharmaceuticals | 0.45 | ||||
| EWTX | Edgewise Therapeutics | 0.28 | ||||
| KROS | Keros Therapeutics | 0.27 | ||||
| VRDN | Viridian Therapeutics | 0.06 | ||||
| JANX | Janux Therapeutics | 0.28 | ||||
| IDYA | Ideaya Biosciences | 0.48 | ||||
| REPL | Replimune | 0.88 | ||||
| NVCT | Nuvectis Pharma | 1.01 | ||||
| PLRX | Pliant Therapeutics | 1.58 | ||||
| KRON | Kronos Bio | 2.00 | ||||
| RVMD | Revolution Medicines | 2.03 | ||||
| GOSS | Gossamer Bio | 3.08 | ||||
| LYRA | Lyra Therapeutics | 4.76 | ||||
| GPCR | Structure Therapeutics | 5.74 |
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.